Korea Health Industry Development Institute (KHIDI)

• Booth: 4373

KHIDI is a Korea MOH(Ministry of Health and Welfare in Korea)-affiliated institute. KHIDI will take the lead in innovating industrial policies and systems, effectively funding healthcare R&D for improved research performance, supporting companies in the development and marketing of products that meet global standards, and strengthening global cooperation for overseas expansion.

 Press Releases

• ProteomeTech Inc. (hereafter Proteometech), the world-leading diagnostic manufacturing company (Jul 18, 2023)

  ProteomeTech Inc. (hereafter Proteometech) is the world-leading diagnostic manufacturing company which aims to contribute to human health and well-being through finding new protein targets for disease prediction. As a manufacturer of award-winning in vitro diagnostic medical devices (Jang Yeongsil Award, New Excellent Technology (NET), World-Class Products and more), Proteometech is a group of talented individuals striving for production of the World's Best Products with strong passion and skills.

  Currently, Proteometech has the world largest number of lines on MAST (Multiple Allergen Simultaneous Test) panel which can detect up to 118 allergens with 128 lines. Proprietary technology which is Parellel Lina Array supports saving time and cost for detecting much allergen in one membrane compared to other competitors. Also, small amount of sample needed for one test which amounts are 50uL/100uL/150uL (based on the panels).

  Not only on human allergy field, but also with animal allergy field, Proteometech provides allergy diagnostics panel “ANITIA Canine IgE and Feline IgE” to detects their pets’ (dog and cat) allergy causes with only 50uL of sample needed. Proteometech is now trying to expand its market on animal allergy in order to penetrate the new market of allergy diagnostics.

  The new product "PROTIA ANA Profile 18" is a product that tests 18 types of Auto Antibodies at a time with only a very small amount of serum or plasma of less than 10 micro using a line blot method. Although the symptoms are very diverse, it was difficult to know the cause and it was difficult to diagnose by examining and comparing various autoimmune-causing proteins individually. Proteomtech has developed a diagnostic technology that simultaneously tests several antibodies that cause autoimmune diseases to compensate for the shortcomings of existing products that individually test only a part of several autoimmune antibodies.

  With various technologies and products line, Proteometech is now moving forward to becoming world leading diagnostic company by cooperating with overseas sales partners locating over 50 countries to expend their market all around the world.

• PCL Revolutionizes Multiplex In Vitro Diagnostics with Cutting-Edge Technology (Jul 18, 2023)

  PCL, a leading biotechnology company based in South Korea, has consolidated its position as a pioneer in the field of multiplex in vitro diagnostics (IVD). Since its inception in 2008, PCL has been at the forefront of IVD multiplex screening, thanks to its revolutionary proprietary SG Cap technology, which specialized in the simultaneous detection of high-risk viruses. With renowned K-GMP and ISO 13485 certifications, PCL maintains an unwavering commitment to strict quality standards.

  At the core of PCL's innovative approach is its cutting-edge SG Cap technology, which enables maximum protein capacity to be achieved in a small space, resulting in exceptional sensitivity. This advance enables up to 64 diagnostics to be performed in a single space, reducing costs, time, space and waste, while guaranteeing superior diagnostic results.

  PCL's product portfolio includes, the HISU solution for high risk viruses screening including HIV at the same time.  can be screened at one time, which is a fully automated multiplex immunoassay platform for mass screening, accommodating up to 540 tests. Thanks to SG Cap technology, HISU offers outstanding speed, environmental friendliness, and simultaneous detection of multiple high-risk viruses. HISU offers blood bank screening, multiple cancer screening​, and serves as a compatible ELISA open system, providing a comprehensive diagnostic solution.

  

  The PCLOK II portable immunoassay system is designed for small and medium-sized hospitals, pet clinics and healthcare centers. Within 30 minutes, PCLOK II enables operators to test 6 samples at the same time, enabling multiplex screening for high risk blood banks, cancer diagnostics, pet antibody detection and respiratory viruses screening. In 2023, PCL introduced a revolutionary comprehensive reagent capable of detecting 6 respiratory viruses simultaneously: Flu A, Flu B, COVID-19, RSV, Adenovirus, and Parainfluenza. This breakthrough is a major step toward preventing the spread of respiratory viruses.

  

  As a respond to the COVID-19 crisis, PCL's Pandemic solution meets the urgent need for rapid, accurate diagnostics. This comprehensive offering includes a COVID-19 antigen rapid kit using saliva samples, an RT-PCR kit and antibody detection kit. In Fact, PCL was the first to develop the first COVID-19 antigen test using human saliva samples (PCL COVID19 Ag Gold), a user-friendly test delivering results in 10 minutes. This convenient and innovative kit has been successfully supplied in over 50 countries worldwide, facilitating effective pandemic management.

  Continuing its commitment to innovation, PCL is committed to revolutionizing in vitro multiplex diagnostics, guaranteeing accurate and effective tests for a wide range of diseases. PCL's unwavering pursuit of excellence underscores its significant contribution to global healthcare.

  For more info, visit: www.pclchip.com or contact: pclchip@pclchip.com

• KHIDI Facilitates Expansion of 35 Korean Diagnostic Device Companies into the American Market with Workshops, Healthcare IR Event, and Exhibition Booth at AACC 2023 in Anaheim, CA, USA (Jul 19, 2023)

  Korea Health Industry Institute (KHIDI), a government organization in the Republic of Korea, has announced a plan to host events supporting Korean medical device companies in their entry into the North American market. These events will be held in conjunction with AACC 2023 Expo, the world's largest annual international academic event and exhibition held in the United States. The AACC Expo showcases a wide range of products, allowing attendees to stay updated on the latest trends in diagnostic devices.

  KHIDI will be hosting the workshop titled "Korea's Continued Leadership in the Diagnostic Field: Showcasing Remarkable Products" at Theater 1 at 2:45pm on July 25th. During this workshop, five Korean in vitro diagnostic device companies, including Seegene, Inc. and PCL, Inc., will present the clinical evaluation results of their exceptional products, highlighting their technological excellence. The purpose of these presentations is to promote the advanced technology and capabilities of these companies and their products. Detailed information on the five companies will be provided separately. Please find the attached document for more details.

  

  Additionally, KHIDI's exhibition booth at AACC will be located at booth number 4373. All participants will have the opportunity to receive the Directory book, which contains key information about 30 Korean companies that are attending AACC 2023.

  For media inquiries or further information, please contact:

  Mr. Shintae Kang

  Researcher

  Korea Health Industry Development Institute(KHIDI)

  movement325@khidi.or.kr

  +82-43-713-8561

 Additional Info